Squarepoint’s Ligand Pharmaceuticals LGND Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $7.21M | Buy |
22,800
+16,406
| +257% | +$3.87M | 0.01% | 1322 |
|
|
2026
Q1 | $1.28M | Buy |
+6,394
| New | +$1.27M | ﹤0.01% | 2567 |
|
|
2025
Q4 | – | Sell |
-17,897
| Closed | -$3.17M | – | 4611 |
|
|
2025
Q3 | $3.17M | Buy |
+17,897
| New | +$2.66M | ﹤0.01% | 1744 |
|
|
2025
Q2 | – | Sell |
-3,494
| Closed | -$367K | – | 4801 |
|
|
2025
Q1 | $367K | Sell |
3,494
-13,305
| -79% | -$1.5M | ﹤0.01% | 3572 |
|
|
2024
Q4 | $1.8M | Buy |
+16,799
| New | +$1.9M | ﹤0.01% | 2521 |
|
|
2023
Q1 | – | Sell |
-3,058
| Closed | -$204K | – | 3525 |
|
|
2022
Q4 | $204K | Sell |
3,058
-15,910
| -84% | -$1.03M | ﹤0.01% | 2781 |
|
|
2022
Q3 | $1.02M | Buy |
+18,968
| New | +$1.12M | 0.01% | 1760 |
|
|
2022
Q2 | – | Sell |
-12,609
| Closed | -$885K | – | 3153 |
|
|
2022
Q1 | $885K | Buy |
12,609
+10,514
| +502% | +$763K | ﹤0.01% | 1663 |
|
|
2021
Q4 | $202K | Sell |
2,095
-4,928
| -70% | -$455K | ﹤0.01% | 2696 |
|
|
2021
Q3 | $610K | Buy |
+7,023
| New | +$543K | ﹤0.01% | 1843 |
|
|
2021
Q2 | – | Sell |
-7,356
| Closed | -$700K | – | 3489 |
|
|
2021
Q1 | $700K | Buy |
7,356
+1,555
| +27% | +$147K | ﹤0.01% | 1778 |
|
|
2020
Q4 | $360K | Sell |
5,801
-10,093
| -64% | -$575K | ﹤0.01% | 2068 |
|
|
2020
Q3 | $945K | Buy |
15,894
+638
| +4% | +$43.5K | 0.01% | 1031 |
|
|
2020
Q2 | $1.06M | Buy |
+15,256
| New | +$967K | 0.02% | 909 |
|
|
2020
Q1 | – | Sell |
-13,480
| Closed | -$877K | – | 2221 |
|
|
2019
Q4 | $877K | Buy |
+13,480
| New | +$901K | 0.01% | 1417 |
|
|
2019
Q3 | – | Sell |
-12,923
| Closed | -$920K | – | 2533 |
|
|
2019
Q2 | $920K | Sell |
12,923
-8,984
| -41% | -$662K | 0.01% | 1307 |
|
|
2019
Q1 | $1.72M | Sell |
21,907
-16,254
| -43% | -$1.23M | 0.02% | 843 |
|
|
2018
Q4 | $3.23M | Buy |
38,161
+34,279
| +883% | +$3.65M | 0.04% | 531 |
|
|
2018
Q3 | $665K | Buy |
3,882
+1,468
| +61% | +$221K | 0.01% | 1178 |
|
|
2018
Q2 | $312K | Buy |
+2,414
| New | +$269K | ﹤0.01% | 1363 |
|
|
2017
Q4 | – | Sell |
-4,163
| Closed | -$354K | – | 2225 |
|
|
2017
Q3 | $354K | Sell |
4,163
-8,852
| -68% | -$701K | 0.01% | 1106 |
|
|
2017
Q2 | $986K | Buy |
+13,015
| New | +$910K | 0.02% | 732 |
|
|
2016
Q1 | – | Sell |
-5,179
| Closed | -$350K | – | 1321 |
|
|
2015
Q4 | $350K | Sell |
5,179
-704
| -12% | -$43.5K | 0.04% | 724 |
|
|
2015
Q3 | $314K | Sell |
5,883
-4,537
| -44% | -$275K | 0.08% | 263 |
|
|
2015
Q2 | $656K | Buy |
+10,420
| New | +$569K | 0.21% | 151 |
|
Other funds holding LGND
JT
CAM
Squarepoint's LGND Position: Q2 2026 in Review
Squarepoint increased its Ligand Pharmaceuticals (LGND) stake by 257% in Q2 2026, buying an estimated $3.87M and bringing the position to 22,800 shares worth $7.21M. The position accounts for 0.01% of the portfolio, ranked #1322.
Squarepoint first reported a position in LGND in Q2 2015 and has held it in 25 quarters since. 417 funds tracked by Wall St. Rank hold LGND as of Q2 2026.
- Squarepoint held 22,800 shares of Ligand Pharmaceuticals worth $7.21M as of Q2 2026.
- Squarepoint bought 16,406 Ligand Pharmaceuticals shares in Q2 2026, an estimated $3.87M.
- Ligand Pharmaceuticals made up 0.01% of Squarepoint's portfolio in Q2 2026, its #1322 holding.
- Squarepoint first reported a position in Ligand Pharmaceuticals in Q2 2015 and has held it in 25 quarters since.
- 417 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.
Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.